.75/.87...gpg
ProCyte Signs European Distribution Agreement
Receives Approval by E. Merck for Iamin(R) Gel in Mexico
REDMOND, Wash., Nov. 16 /PRNewswire/ -- ProCyte Corporation (OTC Bulletin Board: PRCY - news), a leading skin
care and tissue repair company, announced today that Amuchina Sp.A., a pharmaceutical company located in Genoa, Italy has
signed an agreement to market ProCyte's Iamin© gel and OsmoCyte(TM) Pillow dressing wound care products in Italy and
France. ProCyte expects to expand the agreement in the coming year to include other European countries.
Amuchina plans to commence clinical studies early next year and expects to begin purchasing commercial quantities of the
products from ProCyte sometime in late 2000 or early 2001. The agreement contains annual purchase minimums once product
registration is completed.
In a separate development, ProCyte announced that its distribution partner for Latin America, E. Merck KGaA, has obtained
registration for ProCyte's Iamin© Hydrating Gel in Mexico. Similar approval is expected in Peru and Brazil in early 2000.
Commenting on these developments, ProCyte's Chairman and CEO Jack Clifford stated, ``The agreement with Amuchina
represents the last element of our global distribution strategy for wound care products. With Amuchina as our partner, we are
positioned to obtain CE Mark registrations for these products and to begin shipping into what is potentially a very large market.
Regarding the E. Merck announcement, we expect our initial shipment of products to Mexico to occur as early as the first
quarter of next year.'
ProCyte's wound care products are centered on its proprietary copper peptide and hydropolymer technologies. In the past
year, ProCyte has expanded its focus in the plastic surgery and dermatology markets with a series of unique products using its
patented copper peptide complexes. These products include the Complex Cu3(TM) System for use following
microdermabrasion and laser resurfacing; the Neova(TM) Therapy anti-aging line including a night creme and eye therapy;
Tricomin© Advanced Care for Thinning Hair products; and GraftCyte(TM) products for use following hair transplant surgery.
About ProCyte:
ProCyte Corporation is a healthcare products company that develops, manufactures and markets products for tissue repair,
wound care, skin health and hair care. ProCyte's product portfolio includes comprehensive skin care lines for therapeutic care,
pigmentation concerns, anti-aging products and products for thinning hair. The Company's products incorporate its patented
technology and are marketed both directly and through distribution partners.
This report may contain forward-looking statements and should be read in conjunction with the Company's annual report on
Form 10-K and its quarterly reports on Form 10-Q. The Company's results may vary significantly from quarter to quarter and
will depend, among other factors, on product launches and market acceptance, manufacturing contracts and distribution
agreements.
CONTACT: Jack Clifford, Chairman/CEO of ProCyte Corporation, 425-869-1239; or Michael S. Manahan, Principal of
Magnum Financial Group, LLC, 213-488-0443, for ProCyte Corporation. |
